These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 16497294)

  • 41. The clozapine metabolite N-desmethylclozapine displays variable activity in diverse functional assays at human dopamine D₂ and serotonin 5-HT₁A receptors.
    Heusler P; Bruins Slot L; Tourette A; Tardif S; Cussac D
    Eur J Pharmacol; 2011 Nov; 669(1-3):51-8. PubMed ID: 21835172
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation.
    Cosi C; Waget A; Rollet K; Tesori V; Newman-Tancredi A
    Brain Res; 2005 May; 1043(1-2):32-41. PubMed ID: 15862515
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile.
    Claustre Y; Peretti DD; Brun P; Gueudet C; Allouard N; Alonso R; Lourdelet J; Oblin A; Damoiseau G; Françon D; Suaud-Chagny MF; Steinberg R; Sevrin M; Schoemaker H; George P; Soubrié P; Scatton B
    Neuropsychopharmacology; 2003 Dec; 28(12):2064-76. PubMed ID: 12902994
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation.
    Etievant A; Bétry C; Arnt J; Haddjeri N
    Neurosci Lett; 2009 Aug; 460(1):82-6. PubMed ID: 19450663
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.
    Maeda K; Sugino H; Akazawa H; Amada N; Shimada J; Futamura T; Yamashita H; Ito N; McQuade RD; Mørk A; Pehrson AL; Hentzer M; Nielsen V; Bundgaard C; Arnt J; Stensbøl TB; Kikuchi T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):589-604. PubMed ID: 24947465
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912.
    Tadori Y; Kitagawa H; Forbes RA; McQuade RD; Stark A; Kikuchi T
    Eur J Pharmacol; 2007 Nov; 574(2-3):103-11. PubMed ID: 17692841
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors.
    Tadori Y; Forbes RA; McQuade RD; Kikuchi T
    Eur J Pharmacol; 2008 Nov; 597(1-3):27-33. PubMed ID: 18831971
    [TBL] [Abstract][Full Text] [Related]  

  • 48. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
    Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
    Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
    Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dopamine D2(High) receptors moderately elevated by bifeprunox and aripiprazole.
    Seeman P
    Synapse; 2008 Dec; 62(12):902-8. PubMed ID: 18792990
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms.
    Egashira N; Okuno R; Matsushita M; Abe M; Mishima K; Iwasaki K; Nishimura R; Oishi R; Fujiwara M
    Eur J Pharmacol; 2008 Sep; 592(1-3):103-8. PubMed ID: 18644366
    [TBL] [Abstract][Full Text] [Related]  

  • 52. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.
    Assié MB; Dominguez H; Consul-Denjean N; Newman-Tancredi A
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Sep; 373(6):441-50. PubMed ID: 16947046
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism.
    Huang M; Panos JJ; Kwon S; Oyamada Y; Rajagopal L; Meltzer HY
    J Neurochem; 2014 Mar; 128(6):938-49. PubMed ID: 24164459
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling.
    Jordan S; Johnson JL; Regardie K; Chen R; Koprivica V; Tadori Y; Kambayashi J; Kitagawa H; Kikuchi T
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):348-56. PubMed ID: 17070976
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.
    Li Z; Ichikawa J; Dai J; Meltzer HY
    Eur J Pharmacol; 2004 Jun; 493(1-3):75-83. PubMed ID: 15189766
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differential effects of antipsychotic drugs on serotonin-1A receptor-mediated disruption of prepulse inhibition.
    van den Buuse M; Gogos A
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1224-36. PubMed ID: 17194799
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro profile of the antidepressant candidate OPC-14523 at rat and human 5-HT1A receptors.
    Jordan S; Chen R; Koprivica V; Hamilton R; Whitehead RE; Tottori K; Kikuchi T
    Eur J Pharmacol; 2005 Jul; 517(3):165-73. PubMed ID: 15985260
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
    Mamo D; Graff A; Mizrahi R; Shammi CM; Romeyer F; Kapur S
    Am J Psychiatry; 2007 Sep; 164(9):1411-7. PubMed ID: 17728427
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes.
    Lawler CP; Prioleau C; Lewis MM; Mak C; Jiang D; Schetz JA; Gonzalez AM; Sibley DR; Mailman RB
    Neuropsychopharmacology; 1999 Jun; 20(6):612-27. PubMed ID: 10327430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.